Vopratelimab

Vopratelimab (JTX-2011) is a selective humanized immunoglobulin G1-kappa monoclonal antibody that is a potent ICOS agonist. Vopratelimab has a high affinity for inducible T cell CO stimulating factors (ICOS), with an affinity of 0.93 nM for hICOS, 3.7 nM for rat ICOS, and 0.64 nM for mICOS. Vopratelimab has an anti-tumor immune effect and can be used to improve metastatic non-small cell lung cancer.

Methods: Human primary CD4⁺ T cells and Jurkat-ICOS reporter cells were pre-stimulated with anti-CD3 (1 μg/mL) for 24 hours, followed by the addition of vopratelimab (0.1–1 μg/mL) and continued culture for 48–72 hours; T-cell proliferation, cytokine secretion, and AKT/ERK phosphorylation were measured to assess the necessity of Fc-mediated cross-linking and TCR pre-activation.
Results: Vopratelimab requires Fc-mediated cross-linking and T-cell preactivation to exert its agonist effects, promoting CD4⁺ T-cell proliferation and the secretion of cytokines such as IFN-γ, specifically activating the AKT pathway, exhibiting no CD28 superagonist activity, and binding to ICOS with high affinity.[1]

Methods: Mouse tumor models of Sa1/N, B16-SIY, MC38, CT26, and 4T1 were established. Vopratelimab (0.25 mg/kg) was administered intraperitoneally every 3 days for 21 days, and tumor volume and tumor-infiltrating immune cell subsets were monitored.
Results: Vopratelimab monotherapy significantly inhibited tumor growth in Sa1/N and B16-SIY models, specifically reduced the number of Tregs in the tumor microenvironment, increased the effector T cell/Treg ratio, and induced long-term antitumor immune memory.[1]

Human

Monoclonal

Unconjugated